Literature DB >> 8374996

Preparation and cytotoxicity of cyclic hexapeptides, RA derivatives.

H Itokawa1, K Kondo, Y Hitotsuyanagi, A Nakamura, H Morita, K Takeya.   

Abstract

Several aromatic ring substituent modified RA derivatives were prepared from RA-VII (1), RA-V (8) and RA-II (11), and evaluated for cytotoxicity against P388 leukemia and KB cells. In terms of IC50 values, the C zeta methoxyl group of Tyr-3 greatly influenced the activities, while the substituents at the C zeta position of Tyr-6 were less important. One of the derivatives, Tyr-6-C zeta-deoxyRA-V (9, P388, IC50, 0.0025 micrograms/ml) was nearly as active as RA-VII (1, 0.0013 micrograms/ml), and also expressed promising anti-P388 in vivo activity (test/control = 171%, at 25 mg/kg).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8374996     DOI: 10.1248/cpb.41.1266

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  2 in total

1.  Cyclopeptide RA-V inhibits angiogenesis by down-regulating ERK1/2 phosphorylation in HUVEC and HMEC-1 endothelial cells.

Authors:  Grace G L Yue; Jun-Ting Fan; Julia K M Lee; Guang-Zhi Zeng; Tina W F Ho; Kwok-Pui Fung; Ping-Chung Leung; Ning-Hua Tan; Clara B S Lau
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

Review 2.  Design and synthesis of analogues of RA-VII-an antitumor bicyclic hexapeptide from Rubiae radix.

Authors:  Yukio Hitotsuyanagi
Journal:  J Nat Med       Date:  2021-07-10       Impact factor: 2.343

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.